Cite
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
MLA
Choi, Yoo Jin, et al. “Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.” Gut and Liver, vol. 15, no. 3, May 2021, pp. 466–75. EBSCOhost, https://doi.org/10.5009/gnl20070.
APA
Choi, Y. J., Byun, Y., Kang, J. S., Kim, H. S., Han, Y., Kim, H., Kwon, W., Oh, D.-Y., Paik, W. H., Lee, S. H., Ryu, J. K., Kim, Y.-T., Lee, K., Kim, H., Chie, E. K., & Jang, J.-Y. (2021). Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut and Liver, 15(3), 466–475. https://doi.org/10.5009/gnl20070
Chicago
Choi, Yoo Jin, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, et al. 2021. “Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.” Gut and Liver 15 (3): 466–75. doi:10.5009/gnl20070.